drugset / Trial / NCT02157051
Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
Phase 1
Active not recruiting
42 enrolled
University of Washington
Breast Cancer Alliance · collabUnited States Department of Defense · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of multiantigen deoxyribonucleic acid (DNA) plasmid-based vaccine in treating patients with human epidermal growth factor receptor 2 (HER2)-negative stage III-IV breast cancer. Multiantigen DNA plasmid-based vaccine may target immunogenic proteins expressed in breast cancer stem cells which are the component of breast cancer that is resistant to chemotherapy and has the ability to spread. Vaccines made from DNA may help the body build an effective immune response to kill tumor cells.
Timeline
- Start
- 2015-06
- Primary completion
- 2022-11-25
- Completion
- 2026-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine | Vaccine | — | Other |